Burkitt lymphoma: staging and response evaluation

Summary The refinements in both the staging and response evaluation of children with Burkitt lymphoma ( BL ) have contributed to the improvements in treatment outcome observed over the past 40 years. Ziegler and Magrath designed a staging system in the 1970s for children with BL in equatorial Africa. Currently, the most widely used staging system around the world is that described by Murphy in 1980, which was developed for children with non‐Hodgkin lymphoma ( NHL ) of any histology. There are opportunities for refinement in this system, particularly with respect to certain extra‐nodal sites, such as skin and bone. The findings obtained at diagnosis with novel technologies (functional imaging [e.g., positron emission tomography [ PET ]] and minimal residual disease [ MRD ] technology), which are more sensitive with respect to disease detection than historic modalities, also need to be considered. Technological advances have also had impact on the assessment of response evaluation. Standard x‐rays were routinely used in the 1960s; nuclear imaging became widely used in the 1970s; computerized axial tomography was incorporated in the 1980s; PET imaging was incorporated and, in many cases, has replaced gallium/bone scans since 2000; and MRD technology has been explored in some of the most recent clinical trials. There is clearly a need for more clinical data on the use of PET and MRD technology in the determination of response evaluation of children with BL as well as other histological subtypes of NHL . An international working group is currently addressing the refinement of both disease staging and response evaluation in children with NHL .